TrovaGene, Inc. (NASDAQ:TROV) posted its earnings results on Thursday. The medical research company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.02, Bloomberg Earnings reports. TrovaGene had a negative net margin of 10,390.96% and a negative return on equity of 201.07%. The firm had revenue of $0.12 million for the quarter.

TrovaGene (NASDAQ TROV) traded down $0.01 during trading on Friday, hitting $0.67. 510,511 shares of the company’s stock traded hands, compared to its average volume of 581,799. TrovaGene has a 1 year low of $0.61 and a 1 year high of $3.50.

Several equities analysts have commented on the stock. Maxim Group cut shares of TrovaGene from a “buy” rating to a “hold” rating in a research report on Friday. Cantor Fitzgerald reissued an “overweight” rating on shares of TrovaGene in a research report on Tuesday, August 8th.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at

TrovaGene Company Profile

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Earnings History for TrovaGene (NASDAQ:TROV)

Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.